J. E. Thorne, E. Suhler, and M. Skup, Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis, JAMA Ophthalmology, vol.134, issue.11, p.1237, 2016.

A. D. Dick, N. Tundia, and R. Sorg, Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis, Ophthalmology, vol.123, issue.3, pp.655-662, 2016.

A. D. Dick, J. T. Rosenbaum, and A. Ha, Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis, Ophthalmology, vol.125, issue.5, pp.757-773, 2018.

G. J. Jaffe, A. D. Dick, and A. P. Brézin, Adalimumab in Patients with Active Noninfectious Uveitis, New England Journal of Medicine, vol.375, issue.10, pp.932-943, 2016.

Q. D. Nguyen, P. T. Merrill, and G. J. Jaffe, Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. The Lancet, vol.388, pp.1183-1192, 2016.

M. J. Donaldson, J. S. Pulido, D. C. Herman, N. Diehl, and D. Hodge, Pars planitis: a 20-year study of incidence, clinical features, and outcomes, Am. J. Ophthalmol, vol.144, issue.6, pp.812-817, 2007.

B. G. Yuen, V. M. Tham, and E. N. Browne, Association between Smoking and Uveitis: Results from the Pacific Ocular Inflammation Study, Ophthalmology, vol.122, issue.6, pp.1257-1261, 2015.

A. Galor, W. Feuer, and J. H. Kempen, Adverse effects of smoking on patients with ocular inflammation, Br J Ophthalmol, vol.94, issue.7, pp.848-853, 2010.

M. Accorinti, A. A. Okada, J. R. Smith, and M. Gilardi, Epidemiology of Macular Edema in Uveitis, Ocular Immunology and Inflammation, vol.27, issue.2, pp.169-180, 2019.

S. R. Rathinam, M. Babu, and R. Thundikandy, A Randomized Clinical Trial Comparing Methotrexate and Mycophenolate Mofetil for Noninfectious Uveitis, Ophthalmology, vol.121, issue.10, pp.1863-1870, 2014.

S. S. Gangaputra, C. W. Newcomb, and M. M. Joffe, Comparison between Methotrexate and Mycophenolate Mofetil monotherapy for the control of Non-Infectious Ocular Inflammatory Diseases, Am. J. Ophthalmol, 2019.

O. Tomkins-netzer, L. Talat, and A. Bar, Long-Term Clinical Outcome and Causes of Vision Loss in Patients with Uveitis, Ophthalmology, vol.121, issue.12, pp.2387-2392, 2014.

J. H. Kempen, M. L. Van-natta, and M. M. Altaweel, Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial, American Journal of Ophthalmology, vol.160, issue.6, pp.1133-1141, 2015.

R. J. Barry, M. O. Tallouzi, and N. Bucknall, Anti-tumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis

, Cochrane Database of Systematic Reviews, 2018.

L. R. Steeples, P. Spry, R. Lee, and E. Carreño, Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy, International Ophthalmology, vol.38, issue.3, pp.1357-1362, 2018.

V. Calvo-rio, R. Blanco, and E. Beltran, Anti-TNF-therapy in patients with refractory uveitis due to Behcet's disease: a 1-year follow-up study of 124 patients, Rheumatology, vol.53, issue.12, pp.2223-2231, 2014.

N. N. Markomichelakis, P. G. Theodossiadis, and E. Pantelia, Infliximab for chronic cystoid macular edema associated with uveitis, American Journal of Ophthalmology, vol.138, issue.4, pp.648-650, 2004.

D. A. Jabs, R. B. Nussenblatt, and J. T. Rosenbaum,

, Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol. sept, vol.140, issue.3, pp.509-525, 2005.

J. E. Thorne, E. Suhler, M. Skup, S. Tari, D. Macaulay et al., Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis, JAMA Ophthalmol, vol.134, issue.11, pp.1237-1282, 2016.

G. Lopalco, V. Venerito, J. Sota, D. Rigante, S. Guerriero et al., Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy, Clin Exp Rheumatol. déc, vol.36, issue.6, pp.68-73, 2018.

A. D. Dick, N. Tundia, R. Sorg, C. Zhao, J. Chao et al., Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis

, Ophthalmology. mars, vol.123, issue.3, pp.655-62, 2016.

O. M. Durrani, N. N. Tehrani, J. E. Marr, P. Moradi, P. Stavrou et al., Degree, duration, and causes of visual loss in uveitis, Br J Ophthalmol. sept, vol.88, issue.9, pp.1159-62, 2004.

G. J. Jaffe, A. D. Dick, A. P. Brézin, Q. D. Nguyen, J. E. Thorne et al., Adalimumab in Patients with Active Noninfectious Uveitis, N Engl J Med. 8 sept, vol.375, issue.10, pp.932-975, 2016.

Q. D. Nguyen, P. T. Merrill, G. J. Jaffe, A. D. Dick, S. K. Kurup et al., Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial, Lancet. 17 sept, vol.388, pp.1183-92, 2016.

J. E. Thorne, M. Skup, N. Tundia, D. Macaulay, C. Revol et al., Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis, Acta Ophthalmol. août, vol.94, issue.5, pp.331-339, 2016.

J. S. Wittenborn, X. Zhang, C. W. Feagan, W. L. Crouse, S. Shrestha et al., The economic burden of vision loss and eye disorders among the United States population younger than 40 years, Ophthalmology. sept, vol.120, issue.9, pp.1728-1763, 2013.

V. V. Chirikov, R. Shah, Y. Kwon, and D. Patel, Oral corticosteroid exposure and increased risk of related complications in patients with noninfectious intermediate, posterior, or panuveitis: Real-world data analysis, Ophthalmic Epidemiol, vol.26, issue.1, pp.27-46, 2019.

E. B. Suhler, J. E. Thorne, M. Mittal, K. A. Betts, S. Tari et al., Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials, Ophthalmology, vol.124, issue.12, pp.1799-807, 2017.

K. M. Niemeyer, J. A. Gonzales, S. R. Rathinam, M. Babu, R. Thundikandy et al.,

, Quality-of-Life Outcomes From a Randomized Clinical Trial Comparing Antimetabolites for Intermediate, Posterior, and Panuveitis, Am J Ophthalmol. juill, vol.179, pp.10-17, 2017.

, Multicenter Uveitis Steroid Treatment (MUST) Trial Follow-up Study Research Group. Quality of Life and Risks Associated with Systemic Anti-inflammatory Therapy versus

, Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, or Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment Trial and Follow-up Study, Ophthalmology, vol.122, issue.10, pp.1976-86, 2015.

A. Parekh, S. Srivastava, J. Bena, T. Albini, Q. D. Nguyen et al., Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant, JAMA Ophthalmol. mai, vol.133, issue.5, pp.568-73, 2015.

J. H. Kempen, M. M. Altaweel, L. T. Drye, J. T. Holbrook, and D. A. Jabs, Benefits of Systemic Antiinflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study, Ophthalmology, vol.122, issue.10, pp.1967-75, 2015.

B. Hogewind, C. Zijlstra, B. J. Klevering, and C. B. Hoyng, Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis, Eur J Ophthalmol. juin, vol.18, issue.3, pp.429-463, 2008.

A. D. Dick, J. T. Rosenbaum, A. , H. A. Belfort, R. Brézin et al., Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative, Ophthalmology. mai, vol.125, issue.5, pp.757-73, 2018.

E. Diwo, P. Sève, S. Trad, P. Bielefeld, D. Sène et al.,

, Rev Med Interne. sept, vol.39, issue.9, pp.687-98, 2018.

I. Yeung, N. A. Popp, and C. Chan, The role of sex in uveitis and ocular inflammation, Int Ophthalmol Clin, vol.55, issue.3, pp.111-142, 2015.

A. D. Dick, N. Tundia, R. Sorg, C. Zhao, J. Chao et al., Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis

, Ophthalmology. mars, vol.123, issue.3, pp.655-62, 2016.

G. Hatemi, R. Christensen, D. Bang, B. Bodaghi, A. F. Celik et al., 2018 update of the EULAR recommendations for the management of Behçet's syndrome, Ann Rheum Dis, vol.77, issue.6, pp.808-826, 2018.

A. Desbois, C. Terrada, P. Cacoub, B. Bodaghi, and D. Saadoun,

, Rev Med Interne. sept, vol.39, issue.9, pp.738-783, 2018.

Y. Ozyazgan, D. Ucar, G. Hatemi, and Y. Yazici, Ocular Involvement of Behçet's Syndrome: a Comprehensive Review, Clin Rev Allergy Immunol. déc, vol.49, issue.3, pp.298-306, 2015.

M. J. Donaldson, J. S. Pulido, D. C. Herman, N. Diehl, and D. Hodge, Pars planitis: a 20-year study of incidence, clinical features, and outcomes, Am J Ophthalmol. déc, vol.144, issue.6, pp.812-819, 2007.

T. Ness, D. Boehringer, and S. Heinzelmann, Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center, Orphanet J Rare Dis, vol.27, issue.1, p.81, 2017.

B. G. Yuen, V. M. Tham, E. N. Browne, R. Weinrib, D. S. Borkar et al., Association between Smoking and Uveitis: Results from the Pacific Ocular Inflammation Study

, Ophthalmology. juin, vol.122, issue.6, pp.1257-61, 2015.

P. Lin, A. R. Loh, T. P. Margolis, and N. R. Acharya, Cigarette smoking as a risk factor for uveitis, Ophthalmology. mars, vol.117, issue.3, pp.585-90, 2010.

M. Accorinti, A. A. Okada, J. R. Smith, and M. Gilardi, Epidemiology of Macular Edema in Uveitis, Ocul Immunol Inflamm, vol.27, issue.2, pp.169-80, 2019.

O. Tomkins-netzer, L. Talat, A. Bar, A. Lula, S. Taylor et al., Long-term clinical outcome and causes of vision loss in patients with uveitis, Ophthalmology. déc, vol.121, issue.12, pp.2387-92, 2014.

J. H. Kempen, M. L. Van-natta, M. M. Altaweel, J. P. Dunn, D. A. Jabs et al.,

, Factors Predicting Visual Acuity Outcome in Intermediate, Posterior, and Panuveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial, Am J Ophthalmol. déc, vol.160, issue.6, pp.1133-1141, 2015.

S. R. Rathinam, M. Babu, R. Thundikandy, A. Kanakath, N. Nardone et al., A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis, Ophthalmology. oct, vol.121, issue.10, pp.1863-70, 2014.

S. S. Gangaputra, C. W. Newcomb, M. M. Joffe, K. Dreger, H. Begum et al., Comparison between Methotrexate and Mycophenolate Mofetil monotherapy for the control of Non-Infectious Ocular Inflammatory Diseases, Am J Ophthalmol. 22 juill, 2019.

J. Sheppard, A. Joshi, K. A. Betts, S. Hudgens, T. S. Chen et al., Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials, JAMA Ophthalmol, vol.01, issue.6, pp.511-519, 2017.

L. R. Steeples, P. Spry, R. Lee, and E. Carreño, Adalimumab in refractory cystoid macular edema associated with birdshot chorioretinopathy, Int Ophthalmol. juin, vol.38, issue.3, pp.1357-62, 2018.

V. Calvo-río, R. Blanco, E. Beltrán, J. Sánchez-bursón, M. Mesquida et al., Anti-TNF-? therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients, Rheumatology (Oxford). déc, vol.53, issue.12, pp.2223-2254, 2014.

N. N. Markomichelakis, P. G. Theodossiadis, E. Pantelia, S. Papaefthimiou, G. P. Theodossiadis et al., Infliximab for chronic cystoid macular edema associated with uveitis, Am J Ophthalmol, vol.138, issue.4, pp.648-50, 2004.

F. Mackensen, C. Heinz, J. E. Grewing, V. Lorenz, H. Heiligenhaus et al.,

, Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis, Ocul Immunol Inflamm, vol.26, issue.7, pp.1015-1037, 2018.

R. J. Barry, M. O. Tallouzi, N. Bucknall, J. M. Mathers, P. I. Murray et al., Antitumour necrosis factor biological therapies for the treatment of uveitic macular oedema (UMO) for non-infectious uveitis, Cochrane Database Syst Rev, vol.18, p.12577, 2018.

G. Levy-clarke, D. A. Jabs, R. W. Read, J. T. Rosenbaum, A. Vitale et al., Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders, Ophthalmology. mars, vol.121, issue.3, pp.785-796, 2014.

D. A. Jabs, R. B. Nussenblatt, and J. T. Rosenbaum, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol. sept, vol.140, issue.3, pp.509-525, 2005.

B. Madow, A. Galor, W. J. Feuer, M. M. Altaweel, and J. L. Davis, Validation of a photographic vitreous haze grading technique for clinical trials in uveitis, Am J Ophthalmol. août, vol.152, issue.2, pp.170-176, 2011.

R. B. Nussenblatt, A. G. Palestine, C. C. Chan, and F. Roberge, Standardization of vitreal inflammatory activity in intermediate and posterior uveitis, Ophthalmology. avr, vol.92, issue.4, pp.467-71, 1985.

. Vii and . Serment-d'hippocrate,

, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité

, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux

, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte

, Je ne tromperai jamais leur confiance et n'exploiterai pas le pouvoir hérité des circonstances pour forcer les consciences

, Je ne me laisserai pas influencer par la soif du gain ou la recherche de la gloire

, Admise dans l'intimité des personnes, je tairai les secrets qui me seront confiés. Reçue à l'intérieur des maisons, je respecterai les secrets des foyers et ma conduite ne servira pas à corrompre les moeurs

, Je ne prolongerai pas abusivement les agonies. Je ne provoquerai jamais la mort délibérément

, Je n'entreprendrai rien qui dépasse mes compétences. Je les entretiendrai et les perfectionnerai pour assurer au mieux les services qui me seront demandés

, J'apporterai mon aide à mes confrères ainsi qu'à leurs familles dans l'adversité. Que les hommes et mes confrères m'accordent leur estime si je suis fidèle à mes promesses ; que je sois déshonorée et méprisée si j'y manque